RT Journal Article SR Electronic T1 Viral dynamics of acute SARS-CoV-2 infection JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.10.21.20217042 DO 10.1101/2020.10.21.20217042 A1 Stephen M. Kissler A1 Joseph R. Fauver A1 Christina Mack A1 Scott W. Olesen A1 Caroline Tai A1 Kristin Y. Shiue A1 Chaney C. Kalinich A1 Sarah Jednak A1 Isabel M. Ott A1 Chantal B.F. Vogels A1 Jay Wohlgemuth A1 James Weisberger A1 John DiFiori A1 Deverick J. Anderson A1 Jimmie Mancell A1 David D. Ho A1 Nathan D. Grubaugh A1 Yonatan H. Grad YR 2021 UL http://medrxiv.org/content/early/2021/06/06/2020.10.21.20217042.abstract AB Background SARS-CoV-2 infections are characterized by viral proliferation and clearance phases and can be followed by low-level persistent viral RNA shedding. The dynamics of viral RNA concentration, particularly in the early stages of infection, can inform clinical measures and interventions such as test-based screening.Methods We used prospective longitudinal RT-qPCR testing to measure the viral RNA trajectories for 68 individuals during the resumption of the 2019-20 National Basketball Association season. For 46 individuals with acute infections, we inferred the peak viral concentration and the duration of the viral proliferation and clearance phases.Findings According to our mathematical model, we found that viral RNA concentrations peaked an average of 3.3 days (95% credible interval [2.5, 4.2]) after first possible detectability at a cycle threshold value of 22.3 [20.5, 23.9]. The viral clearance phase lasted longer for symptomatic individuals (10.9 days [7.9, 14.4]) than for asymptomatic individuals (7.8 days [6.1, 9.7]). A second test within 2 days after an initial positive PCR substantially improves certainty about a patient’s infection phase. The effective sensitivity of a test intended to identify infectious individuals declines substantially with test turnaround time.Conclusions SARS-CoV-2 viral concentrations peak rapidly regardless of symptoms. Sequential tests can help reveal a patient’s progress through infection stages. Frequent rapid-turnaround testing is needed to effectively screen individuals before they become infectious.Competing Interest StatementJW is an employee of Quest Diagnostics. JW is an employee of Bioreference Laboratories. NDG receives financial support from Tempus to develop SARS-CoV-2 diagnostic tests. SMK, SWO, and YHG have a consulting agreement with the NBA.Funding StatementThis study was funded by the NWO Rubicon 019.181EN.004 (CBFV), a clinical research agreement with the NBA and NBPA (NDG), the Huffman Family Donor Advised Fund (NDG), Fast Grant funding support from the Emergent Ventures at the Mercatus Center, George Mason University (NDG), and the Morris-Singer Fund for the Center for Communicable Disease Dynamics at the Harvard T.H. Chan School of Public Health (YHG).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:In accordance with the guidelines of the Yale Human Investigations Committee, this work with de-identified samples was approved for research not involving human subjects by the Yale Internal Review Board (HIC protocol # 2000028599). This project was designated exempt by the Harvard IRB (IRB20-1407).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode and data are available at https://github.com/gradlab/CtTrajectories https://github.com/gradlab/CtTrajectories